Plain-English translation of NCT06887218 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of 5-Fluorouracil/Leucovorin () plus regorafenib works as well as or better than a standard treatment for advanced colorectal cancer that has spread to other parts of your body. You would be randomly assigned to receive one of two treatment combinations. The study wants to see if the new combination is effective and safe for people whose cancer has progressed despite two previous treatment attempts.
People with advanced colorectal cancer who have tried two rounds of treatment often need other options, but choices are limited. This study is exploring whether combining this medication with another drug could offer better results than the current standard treatment for this situation.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to one of two treatment groups. One group receives an intravenous chemotherapy combination given every 2 weeks along with daily pills taken for 3 weeks followed by 1 week off. The other group receives oral medication taken by mouth on specific days each month along with intravenous infusions twice monthly. Either way, you will continue treatment for up to 12 cycles (roughly 6–12 months) unless your cancer worsens or side effects become too difficult. You'll have regular blood tests and scans to monitor how the treatment is working.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States